Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2021 | Impact of metastases-directed radiation therapy on CDK4/6 inhibitors treatment for mBC

CDK4/6 inhibitors are a standard treatment approach for patients with HR-positive, HER2-negative metastatic breast cancer, and metastases-directed radiotherapy is commonly utilized alongside palliative or radical schedules during systemic treatment. Icro Meattini, MD, University of Florence, Florence, Italy, discusses the impact of metastases-directed radiation therapy on CDK4/6 inhibitors treatment for metastatic breast cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.